Menu
Search
|

Menu

Close
X

Gilead Sciences Inc GILD.OQ (NASDAQ Stock Exchange Global Select Market)

69.20 USD
-0.58 (-0.83%)
As of Nov 16
chart
Previous Close 69.78
Open 69.45
Volume 2,943,541
3m Avg Volume 2,274,639
Today’s High 69.70
Today’s Low 68.94
52 Week High 89.53
52 Week Low 64.27
Shares Outstanding (mil) 1,293.62
Market Capitalization (mil) 91,743.50
Forward P/E 13.14
Dividend (Yield %) 0.57 ( 3.21 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.18 Mean rating from 28 analysts

KEY STATS

Revenue (mm, USD)
FY18
16,332
FY17
26,107
FY16
30,390
FY15
32,639
EPS (USD)
FY18
4.151
FY17
7.686
FY16
9.939
FY15
11.925
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
13.14
29.34
Price to Sales (TTM)
vs sector
4.12
20.58
Price to Book (MRQ)
vs sector
4.01
4.23
Price to Cash Flow (TTM)
vs sector
10.70
21.19
Total Debt to Equity (MRQ)
vs sector
119.49
13.84
LT Debt to Equity (MRQ)
vs sector
107.48
9.93
Return on Investment (TTM)
vs sector
13.07
13.58
Return on Equity (TTM)
vs sector
29.64
15.11

EXECUTIVE LEADERSHIP

John Martin
Chairman of the Board, Since 2018
Salary: $1,253,210.00
Bonus: --
Robin Washington
Chief Financial Officer, Executive Vice President, Since 2014
Salary: $953,231.00
Bonus: --
Kevin Young
Chief Operating Officer, Since 2016
Salary: $1,115,770.00
Bonus: --
John McHutchison
Executive Vice President - Clinical Research, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
Gregg Alton
Executive Vice President - Corporate and Medical Affairs, Chief Patient Officer, Since 2018
Salary: $925,385.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

333 LAKESIDE DR
FOSTER CITY   CA   94404

Phone: +1650.5743000

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

SPONSORED STORIES